Law360, New York (April 08, 2011, 7:18 PM ET) -- Abbott Laboratories agreed in a California federal court on Friday to pay direct purchasers of its HIV drugs Norvir and Kaletra $52 million to resolve a consolidated antitrust class action.
The direct purchasers filed a motion urging the U.S. District Court for the Northern District of California to approve the $52 million deal, which resolves the direct purchasers' allegations that Abbott tried to use its monopoly on Norvir to protect its flagging monopoly power with respect to Kaletra.
Abbott announced in March that it had reached...
Abbott To Pay $52M To Norvir Direct Purchaser Class
To view the full article, take a free trial now.
